Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2020

View Archived Issues

Converting catch and release to PARP traps

Novavax to initiate first-in-human studies of its new coronavirus candidate

Solnatide approved for compassionate use in Austria for treatment of severe COVID-19

Biophytis launches COVA clinical program of Sarconeos in COVID-19

Active compound of WP-1122 reduces coronavirus replication in vitro

Program to prevent the severe respiratory effects of COVID-19 using LAMELLASOME technology

Ariagen patents prodrugs for cancer

Clinical trial application for ACN-00177 approved in the U.K.

Thomas Jefferson University develops COVID-19 vaccine candidate

Cardurion Pharmaceuticals presents CAMK2 inhibitors

MediciNova to initiate clinical trial of ibudilast for COVID-19 ARDS

Enanta Pharmaceuticals identifies compounds for HBV infection

Discovery of a novel antimalarial compound, CHMFL-PI4K-127

Butantan-DV demonstrates safety and immunogenicity in phase II study

Jnana Therapeutics describes new compounds targeting mutant mammalian proteins

Focusing on commonalities to fight projected most common cause of death

New t-PA, u-PA and plasmin inhibitors presented by Alxerion Biotech

OncoImmune cleared to begin phase III study of CD24Fc for hospitalized patients with COVID-19

FDA approves Braftovi for metastatic colorectal cancer with BRAF V600E mutation

Sirnaomics reports phase II interim data on STP-705 for cutaneous squamous cell carcinoma in situ

Aivita offers updated survival data from phase II trial of AV-GBM-1 in glioblastoma

L-Leucine predicts lower mortality in patients with heart failure and preserved ejection fraction

CSL Behring and SAB partner on development of COVID-19 therapeutic candidate SAB-185